N/A N=100 Randomized Treatment

Efficacy of the Nanodropper Device on Pupillary Dilation

Dilation

Bottom Line

View on ClinicalTrials.gov: NCT05274321 ↗

Enrolled (actual)

100

Serious AEs

0.0%

Results posted

Sep 2023

Primary outcome: Primary: Spherical Equivalent — -2.62; -2.28; -0.86; -0.55 Diopters — p=0.22

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Nanodropper (Device); Standard Eye Dropper (Device)
Age: Pediatric · 2+ yrs
Sex: All
Sponsor: University of California, San Francisco
Primary completion: Nov 2021

Outcome Measures

Outcome	Result	p-value
PRIMARY Spherical Equivalent	-2.62; -2.28; -0.86; -0.55; 1.76; 1.73	0.22
PRIMARY Maximum Pupil Diameter	5.95; 6.01; 7.91; 7.81; 1.95; 1.77	0.02 sig
PRIMARY Constriction Percentage	30.44; 31.07; 5.67; 6.26; -24.76; -24.81	0.03 sig
SECONDARY Change in Intraocular Pressure	17.36; 18.13; 18.42; 17.96; 1.06; -0.17	0.25

Summary

Prescription eye drop bottles elute drops that exceed the capacity of the human eye by five times. This study describes performing in clinic dilation using a novel solution for combating medical waste with Nanodropper, an eye drop bottle adapter that creates smaller eye drops.

Eligibility Criteria

Inclusion Criteria

Participants under the age of 18 years old

Exclusion Criteria

Participants 18 years and older
Pupillary or anterior segment abnormality
Participants with pre-existing health conditions that would prevent pupillary dilation.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05274321). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.